Evaluating the Effectiveness of Intranasal Butorphanol in Reducing Chronic Itch
DOI:
https://doi.org/10.2340/actadv.v102.2153Keywords:
chronic itch, pruritus, butorphanolAbstract
Abstract is missing (Short communication)
Downloads
References
Yosipovitch G, Greaves MW, McGlone F. Itch: basic mechanisms and therapy. Boca Raton, CRC Press; 2004.
https://doi.org/10.1201/b14233
Umehara Y, Kiatsurayanon C, Trujillo-Paez JV, Chieosilapatham P, Peng G, Yue H, et al. Intractable itch in atopic dermatitis: causes and treatments. Biomedicines 2021; 9: 229.
https://doi.org/10.3390/biomedicines9030229
Zeidler C, Yosipovitch G, Ständer S. Prurigo nodularis and its management. Dermatol Clin 2018; 36: 189-197.
https://doi.org/10.1016/j.det.2018.02.003
Zachariae R, Lei U, Haedersdal M, Zachariae C. Itch severity and quality of life in patients with pruritus: preliminary validity of a Danish adaptation of the itch severity scale. Acta Derm Venereol 2012; 92: 508-514.
https://doi.org/10.2340/00015555-1221
Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54: 527-531.
https://doi.org/10.1016/j.jaad.2005.12.010
Khanna R, Kwon CD, Patel SP, Belzberg M, Williams KA, Khanna R, et al. Intranasal butorphanol rescue therapy for the treatment of intractable pruritus: a case series from the Johns Hopkins Itch Clinic. J Am Acad Dermatol 2020; 83: 1529-1533.
https://doi.org/10.1016/j.jaad.2020.07.017
Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol 2019; 181: 761-769.
https://doi.org/10.1111/bjd.17744
Beck TC, Hapstack MA, Beck KR, Dix TA. Therapeutic potential of kappa opioid agonists. Pharmaceuticals (Basel) 2019; 12: 95.
https://doi.org/10.3390/ph12020095
Reszke R, Krajewski P, Szepietowski JC. Emerging therapeutic options for chronic pruritus. Am J Clin Dermatol 2020; 21: 601-618.
https://doi.org/10.1007/s40257-020-00534-y
Mathur VS, Kumar J, Crawford PW, Hait H, Sciascia T. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. Am J Nephrol 2017; 46: 450-458.
https://doi.org/10.1159/000484573
Hawi A, Alcorn H, Jr, Berg J, Hines C, Hait H, Sciascia T. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol 2015; 16: 47.
https://doi.org/10.1186/s12882-015-0043-3
Weisshaar E, Szepietowski JC, Bernhard JD, Hait H, Legat FJ, Nattkemper L, et al. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase. J Eur Acad Dermatol Venereol 2022; 36: 453-461.
https://doi.org/10.1111/jdv.17816
Kremer AE. What are new treatment concepts in systemic itch? Exp Dermatol 2019; 28: 1485-1492.
https://doi.org/10.1111/exd.14024
Deeks ED. Difelikefalin: first approval. Drugs 2021; 81: 1937-1944.
https://doi.org/10.1007/s40265-021-01619-6
Kumagai H, Ebata T, Takamori K, Miyasato K, Muramatsu T, Nakamoto H, et al. Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol 2012; 36: 175-183.
Published
How to Cite
License
Copyright (c) 2022 Angelina Labib, Teresa Ju, Zoe Morgan Lipman, Gil Yosipovitch
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
